Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: A review

Critical Care

Volumn 18, Issue 1, 2014, Pages

  Sawa, Teiji ^a   Shimizu, Masaru ^a   Moriyama, Kiyoshi ^b   Wiener Kronish, Jeanine P ^c  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXOU PROTEIN; PHOSPHOLIPASE A2; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG; VIRULENCE FACTOR; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIAL TOXIN; PSEUDOMONAS EXOPROTEIN A PROTEIN, PSEUDOMONAS AERUGINOSA;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CYTOTOXICITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME MECHANISM; GENOTYPE; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; REVIEW; TYPE III SECRETION SYSTEM; UBIQUITINATION; DRUG EFFECTS; GENETICS; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; DRUG RESISTANCE, BACTERIAL; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84924258338     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-014-0668-9     Document Type: Review

References (100)

1. Quartin AA, Scerpella EG, Puttagunta S, Kett DH: A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 2013, 13:561.
2. Grgurich PE, Hudcova J, Lei Y, Sarwar A, Craven DE: Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens. Expert Rev Respir Med 2012, 6:533-555.
3. Barbier F, Andremont A, Wolff M, Bouadma L: Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opinion Pulm Med 2013, 19:216-228.
4. Bassetti M, Taramasso L, Giacobbe DR, Pelosi P: Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti-infective Ther 2012, 10:585-596.
5. Sandiumenge A, Rello J: Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management. Curr Opinion Pulm Med 2012, 18:187-193.
6. Sawa T: The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J Intensive Care 2014, 2:10.
7. Engel J, Balachandran P: Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opinion Microbiol 2009, 12:61-66.
8. Hauser AR: The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nature Rev Microbiol 2009, 7:654-665.
9. Finck-Barbancon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleiszig SM, Wu C, Mende-Mueller L, Frank DW: ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury. Mol Microbiol 1997, 25:547-557.
10. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP: Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 1999, 104:743-750.
11. Sullivan E, Bensman J, Lou M, Agnello M, Shriner K, Wong-Beringer A: Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa . Crit Care Med 2014, 42:48-56.
12. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J: Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa . Clin Microbiol Infect 2008, 14:330-336.
13. Wiener-Kronish JP, Sakuma T, Kudoh I, Pittet JF, Frank D, Dobbs L, Vasil ML, Matthay MA: Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits. J Appl Physiol 1993, 75:1661-1669.
14. Kudoh I, Wiener-Kronish JP, Hashimoto S, Pittet JF, Frank D: Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury. Am J Physiol 1994, 267:L551-L556.
15. Wiener-Kronish JP, Broaddus VC, Albertine KH, Gropper MA, Matthay MA, Staub NC: Relationship of pleural effusions to increased permeability pulmonary edema in anesthetized sheep. J Clin Invest 1988, 82:1422-1429.
16. Nicas TI, Iglewski BH: Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa . Antibiot Chemother 1985, 36:40-48.
17. Nicas TI, Iglewski BH: The contribution of exoproducts to virulence of Pseudomonas aeruginosa . Can J Microbiol 1985, 31:387-392.
18. Fleiszig SM, Wiener-Kronish JP, Miyazaki H, Vallas V, Mostov KE, Kanada D, Sawa T, Yen TS, Frank DW: Pseudomonas aeruginosa -mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S. Infect Immun 1997, 65:579-586.
19. Yahr TL, Goranson J, Frank DW: Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway. Mol Microbiol 1996, 22:991-1003.
20. Hueck CJ: Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 1998, 62:379-433.
21. Galan JE, Collmer A: Type III secretion machines: bacterial devices for protein delivery into host cells. Science 1999, 284:1322-1328.
22. Lee CA: Type III secretion systems: machines to deliver bacterial proteins into eukaryotic cells? Trends Microbiol 1997, 5:148-156.
23. Frank DW: The exoenzyme S regulon of Pseudomonas aeruginosa . Mol Microbiol 1997, 26:621-629.
24. Roy-Burman A, Savel RH, Racine S, Swanson BL, Revadigar NS, Fujimoto J, Sawa T, Frank DW, Wiener-Kronish JP: Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001, 183:1767-1774.
25. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV: Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
26. He J, Baldini RL, Deziel E, Saucier M, Zhang Q, Liberati NT, Lee D, Urbach J, Goodman HM, Rahme LG: The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Nat Acad Sci U S A 2004, 101:2530-2535.
27. Groisman EA, Ochman H: Pathogenicity islands: bacterial evolution in quantum leaps. Cell 1996, 87:791-794.
28. Hovey AK, Frank DW: Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon. J Bacteriol 1995, 177:4427-4436.
29. Goranson J, Frank DW: Genetic analysis of exoenzyme S expression by Pseudomonas aeruginosa . FEMS Microbiol Lett 1996, 135:149-155.
30. Kulasekara BR, Kulasekara HD, Wolfgang MC, Stevens L, Frank DW, Lory S: Acquisition and evolution of the exoU locus in Pseudomonas aeruginosa . J Bacteriol 2006, 188:4037-4050.
31. Sato H, Feix JB, Hillard CJ, Frank DW: Characterization of phospholipase activity of the Pseudomonas aeruginosa type III cytotoxin, ExoU. J Bacteriol 2005, 187:1192-1195.
32. Racusen D: Lipid acyl hydrolase of patatin. Can J Bot 1984, 62:1640.
33. Andrews DL, Beames B, Summers MD, Park WD: Characterization of the lipid acyl hydrolase activity of the major potato ( Solanum tuberosum ) tuber protein, patatin, by cloning and abundant expression in a baculovirus vector. Biochem J 1988, 252:199-206.
34. 2 from potato tissues appears to be patatin. Plant Cell Physiol 1996, 37:347-353.
35. Hirschberg HJ, Simons JW, Dekker N, Egmond MR: Cloning, expression, purification and characterization of patatin, a novel phospholipase A. Eur J Biochem 2001, 268:5037-5044.
36. Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barbancon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, Sawa T: The mechanism of action of the Pseudomonas aeruginosa -encoded type III cytotoxin, ExoU. EMBO J 2003, 22:2959-2969.
37. 2 inhibitors. J Biol Chem 2003, 278:41326-41332.
38. Tamura M, Ajayi T, Allmond LR, Moriyama K, Wiener-Kronish JP, Sawa T: Lysophospholipase A activity of Pseudomonas aeruginosa type III secretory toxin ExoU. Biochem Biophys Res Comm 2004, 316:323-331.
39. Multiple Sequence Alignment by CLUSTALW [ http://www.genome.jp/tools/clustalw/ ]
40. 2 family. Prog Lipid Res 2006, 45:487-510.
41. Banerji S, Flieger A: Patatin-like proteins: a new family of lipolytic enzymes present in bacteria? Microbiol 2004, 150:522-525.
42. Abd H, Wretlind B, Saeed A, Idsund E, Hultenby K, Sandstrom G: Pseudomonas aeruginosa utilises its type III secretion system to kill the free-living amoeba Acanthamoeba castellanii . J Eukaryotic Microbiol 2008, 55:235-243.
43. Matz C, Moreno AM, Alhede M, Manefield M, Hauser AR, Givskov M, Kjelleberg S: Pseudomonas aeruginosa uses type III secretion system to kill biofilm-associated amoebae. ISME J 2008, 2:843-852.
44. Rabin SD, Hauser AR: Pseudomonas aeruginosa ExoU, a toxin transported by the type III secretion system, kills Saccharomyces cerevisiae . Infect Immun 2003, 71:4144-4150.
45. Hauser AR, Engel JN: Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells. Infect Immun 1999, 67:5530-5537.
46. Diaz MH, Shaver CM, King JD, Musunuri S, Kazzaz JA, Hauser AR: Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 2008, 76:4414-4421.
47. Diaz MH, Hauser AR: Pseudomonas aeruginosa cytotoxin ExoU is injected into phagocytic cells during acute pneumonia. Infect Immun 2010, 78:1447-1456.
48. Howell HA, Logan LK, Hauser AR: Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 2013, 4:e00032-00013.
49. Allewelt M, Coleman FT, Grout M, Priebe GP, Pier GB: Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 2000, 68:3998-4004.
50. Shaver CM, Hauser AR: Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 2004, 72:6969-6977.
51. Saliba AM, Nascimento DO, Silva MC, Assis MC, Gayer CR, Raymond B, Coelho MG, Marques EA, Touqui L, Albano RM, Lopes UG, Paiva DD, Bozza PT, Plotkowskiet MC: Eicosanoid-mediated proinflammatory activity of Pseudomonas aeruginosa ExoU. Cellular Microbiol 2005, 7:1811-1822.
52. Plotkowski MC, Brandao BA, de Assis MC, Feliciano LF, Raymond B, Freitas C, Saliba AM, Zahm JM, Touqui L, Bozza PT: Lipid body mobilization in the ExoU-induced release of inflammatory mediators by airway epithelial cells. Microb Pathog 2008, 45:30-37.
53. Henderson FC, Miakotina OL, Mallampalli RK: Proapoptotic effects of P. aeruginosa involve inhibition of surfactant phosphatidylcholine synthesis. J Lipid Res 2006, 47:2314-2324.
54. Saliba AM, de Assis MC, Nishi R, Raymond B, Marques Ede A, Lopes UG, Touqui L, Plotkowski MC: Implications of oxidative stress in the cytotoxicity of Pseudomonas aeruginosa ExoU. Microbes Infect 2006, 8:450-459.
55. Plotkowski MC, Feliciano LF, Machado GB, Cunha LG Jr, Freitas C, Saliba AM, de Assis MC: ExoU-induced procoagulant activity in Pseudomonas aeruginosa -infected airway cells. Eur Respir J 2008, 32:1591-1598.
56. Machado GB, de Assis MC, Leao R, Saliba AM, Silva MC, Suassuna JH, de Oliveira AV, Plotkowski MC: ExoU-induced vascular hyperpermeability and platelet activation in the course of experimental Pseudomonas aeruginosa pneumosepsis. Shock 2010, 33:315-321.
57. Fu H, Coburn J, Collier RJ: The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14-3-3 protein family. Proc Nat Acad Sci U S A 1993, 90:2320-2324.
58. Coburn J, Kane AV, Feig L, Gill DM: Pseudomonas aeruginosa exoenzyme S requires a eukaryotic protein for ADP-ribosyltransferase activity. J Biol Chem 1991, 266:6438-6446.
59. Yahr TL, Vallis AJ, Hancock MK, Barbieri JT, Frank DW: ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system. Proc Nat Acad Sci U S A 1998, 95:13899-13904.
60. Rabin SD, Hauser AR: Functional regions of the Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2005, 73:573-582.
61. Rabin SD, Veesenmeyer JL, Bieging KT, Hauser AR: A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells. Infect Immun 2006, 74:2552-2561.
62. Veesenmeyer JL, Howell H, Halavaty AS, Ahrens S, Anderson WF, Hauser AR: Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity. Infect Immun 2010, 78:3346-3357.
63. Sato H, Feix JB, Frank DW: Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. Biochemistry 2006, 45:10368-10375.
64. Stirling FR, Cuzick A, Kelly SM, Oxley D, Evans TJ: Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin. Cell Microbiol 2006, 8:1294-1309.
65. Benson MA, Komas SM, Schmalzer KM, Casey MS, Frank DW, Feix JB: Induced conformational changes in the activation of the Pseudomonas aeruginosa type III toxin, ExoU. Biophys J 2011, 100:1335-1343.
66. Anderson DM, Schmalzer KM, Sato H, Casey M, Terhune SS, Haas AL, Feix JB, Frank DW: Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU. Mol Microbiol 2011, 82:1454-1467.
67. Gendrin C, Contreras-Martel C, Bouillot S, Elsen S, Lemaire D, Skoufias DA, Huber P, Attree I, Dessen A: Structural basis of cytotoxicity mediated by the type III secretion toxin ExoU from Pseudomonas aeruginosa . PLoS Pathogens 2012, 8:e1002637.
68. Halavaty AS, Borek D, Tyson GH, Veesenmeyer JL, Shuvalova L, Minasov G, Otwinowski Z, Hauser AR, Anderson WF: Structure of the type III secretion effector protein ExoU in complex with its chaperone SpcU. PloS One 2012, 7:e49388.
69. 2 phospholipase. J Biol Chem 2013, 288:26741-26752.
70. Tyson GH, Hauser AR: Phosphatidylinositol 4,5-bisphosphate is a novel coactivator of the Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2013, 81:2873-2881.
71. 2 activities and can function in the absence of any eukaryotic cofactors in vitro. J Bacteriol 2011, 193:4634-4642.
72. Xu Group: Protein structure and function prediction web service RaptorX [ http://raptorx.uchicago.edu ]
73. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR: Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa . Microbiol 2001, 147:2659-2669.
74. Schulert GS, Feltman H, Rabin SD, Martin CG, Battle SE, Rello J, Hauser AR: Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 2003, 188:1695-1706.
75. Wareham DW, Curtis MA: A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Medl Microbiol 2007, 297:227-234.
76. Bradbury RS, Roddam LF, Merritt A, Reid DW, Champion AC: Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa . J Med Microbiol 2010, 59:881-890.
77. Tingpej P, Smith L, Rose B, Zhu H, Conibear T, Al Nassafi K, Manos J, Elkins M, Bye P, Willcox M, Bell S, Wainwright C, Harbour C: Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis. J Clin Microbiol 2007, 45:1697-1704.
78. Jain M, Ramirez D, Seshadri R, Cullina JF, Powers CA, Schulert GS, Bar-Meir M, Sullivan CL, McColley SA, Hauser AR: Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis. J Clin Microbiol 2004, 42:5229-5237.
79. Hu H, Harmer C, Anuj S, Wainwright CE, Manos J, Cheney J, Harbour C, Zablotska I, Turnbull L, Whitchurch CB, Grimwood K, Rose B, ACFBAL study investigators: Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed with cystic fibrosis following newborn screening. Clin Microbiol Infect 2013, 19:266-272.
80. Hauser AR, Cobb E, Bodi M, Mariscal D, Valles J, Engel JN, Rello J: Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa . Crit Care Med 2002, 30:521-528.
81. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH: Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008, 20:714-720.
82. Agnello M, Wong-Beringer A: Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa . PloS One 2012, 7:e42973.
83. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H: Clinical outcomes of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012, 40:1157-1163.
84. Jabalameli F, Mirsalehian A, Khoramian B, Aligholi M, Khoramrooz SS, Asadollahi P, Taherikalani M, Emaneini M: Evaluation of biofilm production and characterization of genes encoding type III secretion system among Pseudomonas aeruginosa isolated from burn patients. Burns 2012, 38:1192-1197.
85. Mitov I, Strateva T, Markova B: Prevalence of virulence genes among Bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa . Brazilian J Microbiol 2010, 41:588-595.
86. Tran QT, Nawaz MS, Deck J, Foley S, Nguyen K, Cerniglia CE: Detection of type III secretion system virulence and mutations in gyrA and parC genes among quinolone-resistant strains of Pseudomonas aeruginosa isolated from imported shrimp. Foodborne Pathogens Dis 2011, 8:451-453.
87. Cho HH, Kwon KC, Kim S, Koo SH: Correlation between virulence genotype and fluoroquinolone resistance in carbapenem-resistant Pseudomonas aeruginosa . Ann Lab Med 2014, 34:286-292.
88. Sawa T, Katoh H, Yasumoto H: V-antigen homologs in pathogenic gram-negative bacteria. Microbiol Immunol 2014, 58:267-285.
89. Sawa T, Yahr TL, Ohara M, Kurahashi K, Gropper MA, Wiener-Kronish JP, Frank DW: Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 1999, 5:392-398.
90. Jiang M, Yao J, Feng G: Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa infection. PLoS One 2014, 9:e96609.
91. Shime N, Sawa T, Fujimoto J, Faure K, Allmond LR, Karaca T, Swanson BL, Spack EG, Wiener-Kronish JP: Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa . J Immunol 2001, 167:5880-5886.
92. Imamura Y, Yanagihara K, Fukuda Y, Kaneko Y, Seki M, Izumikawa K, Miyazaki Y, Hirakata Y, Sawa T, Wiener-Kronish JP, Kohno S: Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 2007, 29:965-968.
93. Frank DW, Vallis A, Wiener-Kronish JP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 2002, 186:64-73.
94. Faure K, Fujimoto J, Shimabukuro DW, Ajayi T, Shime N, Moriyama K, Spack EG, Wiener-Kronish JP, Sawa T: Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa -induced acute lung injury in a rat model. J Immune Based Ther Vaccines 2003, 1:2.
95. Song Y, Baer M, Srinivasan R, Lima J, Yarranton G, Bebbington C, Lynch SV: PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa -infected mice. Eur J Clin Microbiol Infect Dis 2012, 31:1837-1845.
96. Baer M, Sawa T, Flynn P, Luehrsen K, Martinez D, Wiener-Kronish JP, Yarranton G, Bebbington C: An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent anti-bacterial activity. Infect Immun 2008, 77:1083-1090.
97. François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J: Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized, double-blind, placebo-controlled trial. Crit Care Med 2012, 40:2320-2326.
98. Milla CE, Chmiel JF, Accurso FJ, Vandevanter DR, Konstan MW, Yarranton G, Geller DE, for the KB001 Study Group: Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr Pulmonol 2014, 49:650-658.
99. Lee VT, Pukatzki S, Sato H, Kikawada E, Kazimirova AA, Huang J, Li X, Arm JP, Frank DW, Lory S: Pseudolipasin A is a specific inhibitor for phospholipase A2 activity of Pseudomonas aeruginosa cytotoxin ExoU. Infect Immun 2007, 75:1089-1098.
100. Kim D, Baek J, Song J, Byeon H, Min H, Min KH: Identification of arylsulfonamides as ExoU inhibitors. Bioorg Med Chem Lett 2014, S0960-894X:00692-1.